ERS Genomics

ERS Genomics is a leading company in the biotechnology industry, specializing in the commercialization of CRISPR-Cas9 intellectual property. Founded in 2014, the company is spearheaded by Nobel Prize-winner Dr. Emmanuelle Charpentier, a co-inventor and co-owner of the foundational CRISPR-Cas9 technology. The company offers licenses across multiple fields of use, capitalizing on the revolutionary genome editing technology's speed, efficiency, and cost-effectiveness. Their team, with extensive experience in genome editing, business development, and licensing, oversees the licensing of preclinical and clinical stage therapeutic products, drug delivery technologies, and genome editing technologies. For those interested in acquiring a license, reaching out to ERS Genomics is the first step toward exploring the potential of CRISPR-Cas9.